Company Filing History:
2 out of 167 
1 out of 822 
1 out of 4,179 
Years Active: 2015-2016
Title: Alfred Hahn: Innovator in Pharmaceutical Chemistry
Introduction
Alfred Hahn is a notable inventor based in Mannheim, Germany. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 3 patents. His work focuses on innovative compounds that have the potential to address various neurodegenerative and neuropsychiatric disorders.
Latest Patents
Hahn's latest patents include groundbreaking inventions related to hetaryl-substituted guanidine compounds. These compounds are designed to act as binding partners for 5-HT5-receptors, which are crucial in treating and preventing illnesses modulated by 5-HT5-receptor activity. This includes conditions associated with neurodegenerative and neuropsychiatric disorders. Another significant patent involves AGER-peptides, which are derived from the receptor for Advanced Glycation End Products (AGER). These peptides are essential for identifying AGER ligands and can be used in immunization and diagnostic applications.
Career Highlights
Throughout his career, Alfred Hahn has worked with prominent companies such as AbbVie Deutschland GmbH & Co. KG and AbbVie Inc. His expertise in pharmaceutical research has led to advancements in drug development and therapeutic applications.
Collaborations
Hahn has collaborated with esteemed colleagues, including Tariq Ghayur and Bernhard K. Mueller. These partnerships have fostered innovation and contributed to the success of his research endeavors.
Conclusion
Alfred Hahn's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in treating complex medical conditions.